Volume 19 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(1): 131-136
ZHU Qing, ZHU Bin, WU Ting, HONG Jing, LI Nan-fang. Meta-analysis of the relationship between HMGB1 level and systemic vasculitis[J]. Chinese Journal of General Practice, 2021, 19(1): 131-136. doi: 10.16766/j.cnki.issn.1674-4152.001749
Citation: ZHU Qing, ZHU Bin, WU Ting, HONG Jing, LI Nan-fang. Meta-analysis of the relationship between HMGB1 level and systemic vasculitis[J]. Chinese Journal of General Practice, 2021, 19(1): 131-136. doi: 10.16766/j.cnki.issn.1674-4152.001749
shu

Meta-analysis of the relationship between HMGB1 level and systemic vasculitis

doi: 10.16766/j.cnki.issn.1674-4152.001749

  • Hypertension Center, People's Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang, Urumqi, Xinjiang 830001, China

Funds:

 2019D01C105

  • Received Date: 2019-05-08
    Available Online: 2022-02-19
    Abstract
  •   Objective  To systematically evaluated the correlation between high mobility group protein B1 (HMGB1) and systemic vasculitis (SV), and provide basis for evaluating the clinical value of HMGB1 in the diagnosis of SV and disease assessment.  Methods  The studies focused on the association between the HMGB1 level and SV were searched in databases containing PubMed, Medline, Web of Science, Corchrane library, CNKI, Wanfang and VIP from the time of databases establishment to December 2018. Two independent evaluators screened literature according to according to inclusion and exclusion criteria, extracted relevant data, and then used Stata 12.0 software for meta-analysis.  Results  A total of 16 studies were finally included in the meta-analysis. Pooled data suggested HMGB1 levels were significant increased in SV patients compared with inactive patients and healthy controls (HC). The subgroup analysis indicated that HMGB1 levels in small vessel vasculitis and variable vessel vasculitis patients were significantly higher than that in the HC. With the subgroup analyses by region showed that HMGB1 levels were higher in Asia and Europe patients.  Conclusion  The meta-analysis indicates that HMGB1 levels are significant higher in patients with SV than in HC, and can reflect the disease activity. However, further enlargement of the sample size is needed to confirm the results.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    ELEFANTE E, MONTI S, BOND M, et al. One year in review 2017: systemic vasculitis[J]. Clin Exp Rheumatol, 2017, 103(1): 5-26. http://www.researchgate.net/profile/Sara_Monti2/publication/315790273_One_year_in_review_2017_Systemic_vasculitis/links/5a377e3445851532e832bf57/One-year-in-review-2017-Systemic-vasculitis.pdf
    [2]
    HATEMI G, ESATOGLU S N, YAZICI Y. Biomarkers in vasculitis[J]. Curr Opin Rheumatol, 2018, 30(1): 30-35. doi: 10.1097/BOR.0000000000000447
    [3]
    KURET T, LAKOTA K, ŽIGON P, et al. Insight into inflammatory cell and cytokine profiles in adult IgA vasculitis[J]. Clin Rheumatol, 2019, 38(2): 331-338. doi: 10.1007/s10067-018-4234-8
    [4]
    DEMIR S, SAG E, DEDEOGLU F, et al. Vasculitis in systemic autoinflammatory diseases[J]. Front Pediatr, 2018, 377(6): 1-10. doi: 10.3389/fped.2018.00377/pdf
    [5]
    DIENER K R, AL-DASOOQI N, LOUSBERG E L, et al. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer[J]. Immunol Cell Biol, 2013, 91(7): 443-450. doi: 10.1038/icb.2013.25
    [6]
    SUN X J, ZENG H Y, WANG Q S, et al. Glycyrrhizin ameliorates inflammatory pain by inhibiting microglial activation-mediated inflammatory response via blockage of the HMGB1-TLR4-NF-kappa B pathway[J]. Exp Cell Res, 2018, 369(1): 112-119. doi: 10.1016/j.yexcr.2018.05.012
    [7]
    VIJAY N, CHANDE A. A hypothetical new role for single-stranded DNA binding proteins in the immune system[J]. Immunobiology, 2018, 223(11): 671-676. doi: 10.1016/j.imbio.2018.07.013
    [8]
    WANG F Y, LI X Z, HUANG L S, et al. High-mobility group protein box 1 is upregulated in children with henoch-schonlein purpura[J]. Pediat Aller Imm Pul, 2018, 31(2): 66-72. http://smartsearch.nstl.gov.cn/paper_detail.html?id=5a823debb19a8d5e590accf99533614f
    [9]
    WANG C, GOU S J, CHANG D Y, et al. Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis[J]. Arthritis Care Res, 2013, 65(11): 1828-1834. doi: 10.1002/acr.22187
    [10]
    DE SOUZA A, WESTRA J, BIJZET J, et al. Is serum HMGB1 a biomarker in ANCA-associated vasculitis?[J]. Arthritis Res Ther, 2013, 15(5): R104. doi: 10.1186/ar4284
    [11]
    WIBISONO D E, LAMPRECHT P, HOLLE J U, et al. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis[J]. Ann Rheum Dis, 2010, 69(10): 1888-1889. doi: 10.1136/ard.2009.119172
    [12]
    EGUCHI T, NOMURA Y, HASHIGUCHI T, et al. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome[J]. Pediatr Infect Dis J, 2009, 28(4): 339-341. doi: 10.1097/INF.0b013e31818ffe60
    [13]
    HOSHINA T, KUSUHARA K, IKEDA K, et al. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease[J]. Scand J Rheumatol, 2008, 37(6): 445-449. doi: 10.1080/03009740802144143
    [14]
    DE SOUZA A W, FÉLIX P S, DE FRANA N R, et al. High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations[J]. Rheumatology, 2015, 54(12): 2151-2155. http://smartsearch.nstl.gov.cn/paper_detail.html?id=da49931fce08241f7970e81f36346812
    [15]
    DE SOUZA A W, KS VDG, BROUWER E, et al. High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins[J]. Arthritis Res Ther, 2015, 17(1): 158. doi: 10.1186/s13075-015-0672-8
    [16]
    STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. doi: 10.1007/s10654-010-9491-z
    [17]
    HOZO S P, DJULBEGOVIC B, HOZO I. Estimating the mean and variance from the median, range, and the size of a sample[J]. BMC Med Res Methodol, 2005, 5(1): 13. doi: 10.1186/1471-2288-5-13
    [18]
    WHITLOCK R P, CHAN S, DEVEREAUX P J, et al. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials[J]. Eur Heart J, 2008, 29(21): 2592-2600. doi: 10.1093/eurheartj/ehn333
    [19]
    HIGGINS J P, THOMPSON S G. Quantifying heterogeneity in a meta-analysis[J]. Stat Med, 2002, 21(11): 1539-1558. doi: 10.1002/sim.1186
    [20]
    黄教文, 孙建平, 高延霞, 等. 高迁移率族蛋白B1在抗中性粒细胞胞浆抗体相关性小血管炎患者血清中的表达水平及临床意义[J]. 中华临床医师杂志(电子版), 2013, 7(1): 188-189. doi: 10.3877/cma.j.issn.1674-0785.2013.01.076
    [21]
    李艳飞, 金莲花, 杨思睿, 等. 血清HMGB1、MIF、IL-6水平在川崎病患儿中的临床意义[J]. 中国实验诊断学, 2013, 17(6): 1087-1090. doi: 10.3969/j.issn.1007-4287.2013.06.034
    [22]
    甘世伟, 赵林胜, 王燕. HMGB1在过敏性紫癜患儿血清中的表达及其临床意义[J]. 重庆医科大学学报, 2014, 39(12): 1767-1770. https://www.cnki.com.cn/Article/CJFDTOTAL-ZQYK201412020.htm
    [23]
    王凤英, 蒋星美, 鲁曼. 高迁移率族蛋白1在过敏性紫癜患儿血清中的表达及意义[J]. 中国当代儿科杂志, 2015, 17(8): 792-795. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ201508006.htm
    [24]
    DE SOUZA A, LEEUW K, VAN TIMMEREN M, et al. Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis[J]. PLoS One, 2014, 9(4): e96067. doi: 10.1371/journal.pone.0096067
    [25]
    HENES F, CHEN Y, BLEY T, et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's)[J]. Ann Rheum Dis, 2011, 70(11): 1926-1929. doi: 10.1136/ard.2010.146456
    [26]
    CHEN T, GUO Z P, WANG W J, et al. Increased serum HMGB1 levels in patients with Henoch-Schönlein purpura[J]. Exp Dermato, 2014, 23(6): 419-423. doi: 10.1111/exd.12422
    [27]
    YANG H, WANG H, CHAVAN S S, et al. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule[J]. Mol Med, 2015, 21(Suppl 1): S6-S12. http://www.ncbi.nlm.nih.gov/pmc/picrender.fcgi?artid=PMC4661054&blobtype=pdf
    [28]
    WANG C, DE SOUZA A W, WESTRA J, et al. Emerging role of high mobility group box 1 in ANCA-associated vasculitis[J]. Autoimmun Rev, 2015, 14(11): 1057-1065. doi: 10.1016/j.autrev.2015.07.010
    [29]
    ANDERSSON U, TRACEY K J. HMGB1 is a therapeutic target for sterile inflammation and infection[J]. Annu Rev Immunol, 2011, 29(1): 139-162. doi: 10.1146/annurev-immunol-030409-101323
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (174) PDF downloads(6) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return